Diamonds and Dogs

9/20/17

A biotech shooting higher. Alnylam Pharmaceuticals (ALNY) is up 31% to new highs after the company unveiled positive topline results from a Phase 3 study of patisiran, which is being developed for patients with hereditary ATTR amyloidosis with polyneuropathy. In other words, the drug helps patients suffering from a life-threatening genetic disease that affects the peripheral nerves.

Bed Bath & Beyond (BBBY) is going to the mattresses. The home furnishing retailer is down 15% to new lows after lowering current quarter and full year guidance. The company will make 77 per share for the quarter, 18 cents worse than consensus. Revenues will come in down 2% year over year. Bed Bath & Beyond also issued downside guidance for the full year, now seeing earnings estimates of $3.00 a share down from consensus of $4.00 a share.

Diamonds and Dogs market commentary is a journal of daily observations on anything that happens to be of interest to our author. Obviously, our primary focus is the stock market and world economic events, but for this page we have no defined topics. We want this page to be dedicated to the interests, concerns, and possibly to the financial gain of our clients and friends. All comments contained herein are for informational purposes only, and should not be considered as a solicitation to buy or sell any security. The firm does not guarantee the accuracy or completeness of the information or make any warranties regarding results from it's usage.